东方金诚公告［2025］0326 号 东方金诚国际信用评估有限公司（以下简称"东方金诚"）受托对北京北陆药业股份有限公司 （以下简称"北陆药业"或"公司"）及其发行的"北京北陆药业股份有限公司向不特定对象发行 可转换公司债券"（以下简称"北陆转债"）进行了信用评级。2025 年 6 月 16 日，东方金诚对北 陆药业主体及"北陆转债"进行了定期跟踪评级，维持公司主体信用等级为 A，评级展望稳定，维 持"北陆转债"信用等级为 A，评级结果自评级报告日起至到期兑付日有效。 东方金诚关注到，2025 年 7 月 15 日，公司发布《北京北陆药业股份有限公司关于提前赎回"北 陆转债"的公告》（以下简称"公告"），公告指出自 2025 年 6 月 17 日至 2025 年 7 月 14 日，公 司股票在任意连续三十个交易日中已有十五个交易日的收盘价不低于当期转股价格 7.02 元/股的 130%（含 130%，即 9.13 元/股），已触发"北陆转债"有条件赎回条款；2025 年 7 月 14 日，公 司召开第九届董事会第二次会议，审议通过了《关于提前赎回"北陆转债"的议案》，结合当前市 场及公司实际情况，为优化公司资 ...

证券日报网讯北陆药业（300016）8月20日在互动平台回答投资者提问时表示，医未医疗成立时的注册 资本为100万元，目前的注册资本为112.5985万元人民币。 ...

每经AI快讯，有投资者在投资者互动平台提问：医未医疗注册资本为112.5985万元人民币，这应该是 2017年成立时注册资本吧，经过2022年C轮融资后注册资本没有变更过吗？ 北陆药业（300016.SZ）8月20日在投资者互动平台表示，医未医疗成立时的注册资本为100万元，目前 的注册资本为112.5985万元人民币。 （文章来源：每日经济新闻） ...

基因测序板块领涨，上涨2.14%，其中透景生命上涨17.78%，益佰制药上涨10.07%，北陆药业上涨 10.02%，南京新百、利欧股份、广生堂涨超9%。（第一财经AI快讯） ...

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

北陆药业回复：感谢您的关注。医未医疗注册资本为112.5985万元人民币，公司目前持有医未医疗 14.9881%的股份，投资金额为3,000万元人民币。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，北陆药业(300016)08月18日在投资者关系平台上答复投资者关心的问题。 投资者提问：请问，参股公司深圳医未医疗科技公司的注册资本多少？员工人数多少？公司参股14％， 资金多少？ ...

来源：金融界 公司回答表示：感谢您的关注。医未医疗注册资本为112.5985万元人民币，公司目前持有医未医疗 14.9881%的股份，投资金额为3,000万元人民币。 金融界8月18日消息，有投资者在互动平台向北陆药业提问：请问，参股公司深圳医未医疗科技公司的 注册资本多少？员工人数多少？公司参股14％，资金多少？ ...

Group 1 - The core viewpoint of the news is that the brain-computer interface concept stocks in the A-share market have shown strong performance, with several companies experiencing significant price increases [1] Group 2 - Company performance highlights include: - Innovation Medical (002173) saw a price increase of 10.00%, with a total market capitalization of 9.995 billion and a year-to-date increase of 184.55% [2] - Pulite (002324) increased by 7.51%, with a market cap of 15.9 billion and a year-to-date increase of 50.88% [2] - Chengyitong (300430) rose by 6.65%, with a market cap of 6.657 billion and a year-to-date increase of 59.67% [2] - Saily Medical (603716) increased by 5.45%, with a market cap of 5.878 billion and a year-to-date increase of 326.18% [2] - Sanbo Brain Science (301293) rose by 3.79%, with a market cap of 12.9 billion and a year-to-date increase of 44.76% [2] - The MACD golden cross signal formation indicates a positive trend for these stocks [1]

Group 1 - The latest stock price of Beilu Pharmaceutical is 9.79 yuan, with a slight increase of 0.01 yuan, representing a 0.10% rise compared to the previous trading day [1] - The stock opened at 9.88 yuan, reached a high of 10.25 yuan, and a low of 9.69 yuan, with a trading volume of 674 million yuan and a fluctuation of 5.73% [1] - Beilu Pharmaceutical primarily engages in chemical pharmaceuticals, with products including contrast agents, hypoglycemic drugs, and anti-anxiety medications [1] Group 2 - The company's subsidiary, Zhejiang Haichang Pharmaceutical, recently received approval from the National Medical Products Administration for the marketing application of Iopamidol [1] - Iopamidol is a low-osmolar, non-ionic water-soluble contrast agent used for CT enhancement imaging and angiography, noted for its lower side effects, making it suitable for patients with renal impairment and high-risk conditions [1] Group 3 - On August 12, the net outflow of main funds was 32 million yuan, with a cumulative net outflow of 85.7 million yuan over the past five days [1]

Group 1: Resumption of Trading - Jin Chengzi plans to acquire 55% stake in Samit and will resume trading tomorrow; Samit specializes in high-precision fast-reflecting mirror business [1] - Quzhou Development intends to purchase 95.4559% of Xian Dao Electronics and will resume trading tomorrow; Xian Dao focuses on the R&D of sputtering targets and evaporation materials for vacuum coating [1] Group 2: Mergers, Acquisitions, and Capital Increases - China Shipbuilding's dissenting shareholders' acquisition request price is set at 30.02 yuan per share [2] - Jiangsu Suopu plans to raise no more than 1.5 billion yuan through a private placement for the ethylene acetate and EVA integration project (Phase I) [3] - Guangli Microelectronics is acquiring 100% of LUCEDA NV to strategically position itself in silicon photonics technology [4] Group 3: Share Buybacks, Increases, and Equity Transfers - Zhenlei Technology has raised its share buyback price from 38.13 yuan per share to 74 yuan per share [5] - Fuanna has conducted its first buyback of 1 million shares [6] - Shaanxi Jinye plans to repurchase shares worth between 40 million and 70 million yuan, with loans not exceeding 63 million yuan [7] - Donghua Energy's controlling shareholder's concerted action party has received a commitment letter for a special loan to increase holdings, not exceeding 225 million yuan [8] - Taimusi's controlling shareholder intends to transfer 29.99% of the company's shares, with Guangzhou State-owned Assets Supervision and Administration Commission becoming the actual controller [9] Group 4: External Investments and Daily Operations - Haikang obtained the clinical trial approval notice for the innovative drug HSK47977 tablets [10] - Rundou Co., Ltd. received approval for the listing application of glucosamine sulfate sodium chloride compound as a chemical raw material drug [11] - Beilu Pharmaceutical's subsidiary Haichang Pharmaceutical's iodine mepivacaine chemical raw material drug has been approved for listing [12] - Baiyun Airport signed a cooperation contract with China Duty Free Group for the operation of the T3 terminal's outbound duty-free project [13] - Guoshield Quantum plans to sign a sales contract worth 76.5418 million yuan with China Telecom Quantum Group for the sale of quantum key distribution hardware and software [14] Group 5: Performance Changes - Zhenlei Technology's net profit for the first half of 2025 is 62.3197 million yuan, a year-on-year increase of 1006.99%; the company continues to strengthen its advantages in special fields such as data links, electronic countermeasures, wireless communication terminals, next-generation radios, and phased array communications, achieving significant growth in orders and projects [15] - Jingchen Co., Ltd. reported a net profit of 497 million yuan for the first half of the year, a year-on-year increase of 37.12% [16] - China Unicom's net profit for the first half of 2025 is 6.349 billion yuan, a year-on-year increase of 5.1% [17] - Shuanghui Development's net profit for the first half of the year is 2.323 billion yuan, a year-on-year increase of 1.17%; the company plans to distribute 6.5 yuan per 10 shares [18] - Jinlongyu's net profit for the first half of the year is 1.756 billion yuan, a year-on-year increase of 60.07% [19]